PHOENIX and VANCOUVER, British Columbia, April 15, 2014 (GLOBE NEWSWIRE) -- Eternity Healthcare Inc. (OTC:ETAH), a leading medical device and diagnostic company with special focus on diabetes management, announced today that it has signed a Letter of Intent (LOI) to license technologies from Kinexus Theranostics.
Kinexus Theranostics is the leader in Kinases discovery and functional testing using blood or tissue. Using blood or tissue samples, the whole parameters of diabetes is illustrated against respective kinase action. This technology utilizes a number of cellular proteins known as kinases in the blood, several years before any changes have occurred with the blood sugar level. Based on the changes to those proteins, one can decide to change their diet and exercise. The test detects diabetes far earlier than any currently available test on the market.
There are estimated 28 million diabetics in the United States and this number is growing. The worldwide number of diabetics is estimated to be over 250 million and will reach to 430 million by year 2030, according to World Health Organization. Diabetic patients are divided into two categories; type I and type II. About 90% of current diabetes are type II. Type II diabetes, the pancreas does not produce enough insulin or the body does not properly use the insulin it makes. Consequently, instead of being used for energy, glucose (sugar) builds up in the blood that can lead to complications such as blindness, heart disease, kidney problems, nerve damage and erectile dysfunction. Type II diabetes is directly linked to obesity, diet and a sedentary life style. Type II diabetes can be prevented if appropriate measures are taken before the occurrence of disease. Current tests for diagnosis of Type II diabetes is based on measuring blood sugar level. However once the sugar level is detected to be high, it is too late to stop the diabetes. A test that measures the changes in pancreas function or insulin uptake using kinases, can detect the appearance of the disease several years before the changes in blood sugar level and consequently, if proper diet is taken, the disease can be prevented.
Dr. Salari, C.E.O. states that "Eternity Healthcare Inc. will use the parameters of blood proteins known as kinases, in the extremely fast and reliable way to detect occurrence or susceptibility to diabetes." Dr. Salari went on to state "Eternity Healthcare Inc. is the first company in the world to use this novel test for the detection of diabetes".
About Kinexus
Kinexus is a private company involved in diagnosis and assay for over 700 protein kinases. Some of these kinases are involved in diabetes, while others are involved in cancer, neurodegeneration and cardiovascular diseases. For further information, visit www.kinexus.ca
About Eternity Healthcare
Eternity Healthcare or the "Company" (OTC:ETAH) is a healthcare company with technologies in medical devices and diagnostics. Our most advanced product is a needle-free injection system known as Softjet™ or Comfort-in™. Our products are sold to healthcare professionals, for use in physicians' offices, pharmacies, and to consumers directly. More information on Eternity Healthcare, visit the Company's website; www.eternityhealthcare.com
Safe Harbor Statement
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.